Sema4 debuts genetic testing services

Stamford-headquartered Sema4 has introduced a line of genomic testing services and digital tools designed to aid oncologists treating cancer patients from the risk assessment to the remission monitoring process.

“Sema4’s mission to help physicians implement precision medicine is built on our deep foundation in data science and developing genomic tests,” said Eric Schadt, founder and CEO of Sema4. “Our team’s expertise in data mining, analysis, machine learning, and predictive modeling gives us a unique advantage in generating and making sense of information in ways that will give oncologists an edge in battling cancer, particularly when combined with advanced genomic profiling.”